[Possible exploitation of a pharmacovigilance center concerning the risk of teratogenesis].
Evaluating a teratogenic risk remains a difficult problem, since the existing data in this field is fragmentary. One can consider using the material obtained by the follow-up of pregnancies which have motivated a telephone consultation to an Information Center. The material could, within limits, be used to give some security. If the present numbers do not change, it would take around four years to obtain data concerning 150 women exposed during the first trimester of their pregnancy.
Guilhem
D
D
Département de Pharmacologie, Centre Régional de Pharmacovigilance, Pitié-Salpêtrière, Paris.
Castex
V
V
Soubrié
C
C
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology* / Q000209:etiology; D003625:Data Collection / Q000379:methods; D004346:Drug Information Services / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011297:Prenatal Exposure Delayed Effects; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D013723:Teratogens
D013723:Teratogens
Exploitation possible d'un centre de pharmacovigilance concernant le risque de tératogenèse.